April 10-11 – The Health and Human Services Department (HHS); Office of the Secretary of Health and Human Services' National Vaccine Program Office is holding a meeting on "Vaccine Safety Evaluation: Post-marketing Surveillance.”
April 11 – The FDA is holding the Anti-Infective Drugs Advisory Committee to provide advice and recommendations to the agency on regulatory issues in Rockville.
April 11 – The FDA is having a meeting of the Pediatric Advisory Committee to review adverse event reports for fluvastatin (LESCOL) and octreotide (SANDOSTATIN) and to receive updates to adverse event reports for orlistat (XENICAL) and oxybutynin (DITROPAN).
April 11 – The Senate Finance Committee for Medicare Advantage Program is holding a full committee hearing on "An Examination of the Medicare Advantage Program." Witnesses: Peter Orszag, director of the Congressional Budget Office; Glenn Hackbarth, chairman of the Medicare Payment Advisory Commission; Debra Draper, associate director at the Center for Studying Health Systems Change; and Steven Udvarhelyi, senior vice president and chief medical officer for Independence Blue Cross.
April 12 – The FDA is holding a Arthritis Advisory Committee. The committee will discuss the new drug application (NDA) 21-389/21-772, ARCOXIA (etoricoxib), Merck & Co., Inc., proposed treatment for the relief of signs and symptoms of osteoarthritis.
April 12 – The Centers for Medicare and Medicaid Services and HHS are holding a listening session on the “Draft Plan for Medicare Hospital Value-Based Purchasing.”
April 14-18 – The American Association for Cancer Research (AACR) is hosting their annual meeting in Los Angeles.
